Serimmune will discuss its Serum Epitope Repertoire Analysis (SERA) platform and how it can be applied in various studies to gain insight into past and present humoral immune responses in individuals and cohorts.
Company to chair session on new vaccine development on Tuesday, November 14, 2023, at 3:20 p.m. ET
--(BUSINESS WIRE)-- WHAT: SerImmune will discuss its Serum Epitope Repertoire Analysis (SERA) platform and how it can be applied in various studies to gain insight into past and present humoral immune responses in individuals and cohorts. The new vaccine development session will be led by Dr. John Shon and will review how SERA allows for the detection of an unlimited number of B cell immune responses in a single assay, enabling comparative immunomics and precision immunology.
WHY: Individuals are exposed to a wide variety of environmental, infectious, vaccines and therapeutic agents stimulating humoral immune response. Whether studying longitudinal samples, novel formulations of vaccines or boosters, pre-clinical vs. clinical vaccine responses, or vaccine vs. natural infection, SERA enables comparative, high-throughput, high-resolution analysis of epitopes to enable precision immunology, supporting the next generation of vaccine development.
WHO: Serimmune and Vaccine Summit 2023 will bring together experts in the field of vaccine research as well as industry leaders to address current issues facing vaccine development. The “New Vaccine Development” session will be led by Dr. John Shon, Chief Technology Officer, Serimmune.
WHEN: “SERA: universal serology enabling high-throughput, antigen agnostic studies of adaptive immune responses” will be held Tuesday, November 14, 2023, at 3:20 p.m. ET / 12:20 p.m. PT.
WHERE: Vaccine Summit 2023 at the Sheraton Boston Needham Hotel, Grand Ballroom.
To register click here: https://scientiameetings.com/conferences/vaccines/
About Serimmune
Serimmune is a leader in understanding antibody repertoire and is focused on identifying and exploiting the universe of relationships between antibodies and antigens. The company’s Serum Epitope Repertoire Analysis (SERA) technology platform applies bacterial display peptide libraries, next generation sequencing, machine learning and custom bioinformatics to reveal the many diverse antigens stimulating immunity. Serimmune’s human immunity map is a growing database that can be interrogated to uncover disease information for the development of multiplex diagnostics, vaccines and therapeutics. The company was founded in 2014 and is backed by investors such as Illumina Ventures, LabCorp, and Merck. For more information visit serimmune.com or follow us on Facebook, Twitter and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231108820343/en/
Source: Serimmune
View this news release online at:
http://www.businesswire.com/news/home/20231108820343/en
